Literature DB >> 6145097

Identity of the proliferating cell nuclear antigen and cyclin.

M B Mathews, R M Bernstein, B R Franza, J I Garrels.   

Abstract

Studies of growth regulation and cellular transformation will be assisted by the identification of proteins that are preferentially synthesized in dividing cells. The 'proliferating cell nuclear antigen' ( PCNA ), distinguished by its apparent association with cell division, is defined by reaction with an antibody found in the autoimmune disease systemic lupus erythematosus (SLE). This antibody reacts with proliferating cells including tumour cells but gives weak or undetectable immunofluorescence with resting cells of normal tissues. Peripheral blood lymphocytes are devoid of PCNA until activated by mitogen in vitro. In synchronized cultures its level and distribution fluctuate through the cell cycle, with a striking accumulation in the nucleolus late in the G1 phase and early in the S phase. Many of these properties are shared by ' cyclin '. This nuclear protein, identified by its position in a two-dimensional separation of cell proteins, is also transformation-sensitive and is preferentially synthesized in the S phase. We establish here that PCNA and cyclin are identical, and show that PCNA is an acidic nuclear protein of apparent molecular weight 35,000.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145097     DOI: 10.1038/309374a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  140 in total

1.  Immunohistochemical analysis, human papillomavirus DNA detection, hormonal manipulation, and exogenous gene expression of normal and dysplastic human cervical epithelium in severe combined immunodeficiency mice.

Authors:  J A Taylor; K Tewari; S Y Liao; C C Hughes; L P Villarreal
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Immunohistochemical study of Cell Cycle Modulators in G(1)-S Transition in Clinical Breast Cancer Tissue.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

3.  Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus.

Authors:  J M Parent; T W Yu; R T Leibowitz; D H Geschwind; R S Sloviter; D H Lowenstein
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

Review 4.  Relative paradigms between autoantibodies in lupus and autoantibodies in cancer.

Authors:  E M Tan; F-D Shi
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

Review 5.  Proliferation indices in malignant lymphomas.

Authors:  J Crocker
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

6.  Transcription factors RFX1/EF-C and ATF-1 associate with the adenovirus E1A-responsive element of the human proliferating cell nuclear antigen promoter.

Authors:  C Labrie; B H Lee; M B Mathews
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

7.  Increased epidermal cell proliferation in normal human skin in vivo following local administration of interferon-gamma.

Authors:  J N Barker; J R Goodlad; E L Ross; C C Yu; R W Groves; D M MacDonald
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

8.  PCNA-Ub polyubiquitination inhibits cell proliferation and induces cell-cycle checkpoints.

Authors:  Zhoushuai Qin; Zhiqiang Bai; Ying Sun; Xiaohong Niu; Wei Xiao
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

9.  Cell death induced by gamma irradiation of developing skeletal muscle.

Authors:  M Olivé; R Blanco; R Rivera; C Cinos; I Ferrer
Journal:  J Anat       Date:  1995-08       Impact factor: 2.610

10.  Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index.

Authors:  V Gorgoulis; V Zoumpourlis; G Rassidakis; A Karameris; C Barbatis; D A Spandidos; C Kittas
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.